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Case Report
Losartan associated anaphylaxis and angioneurotic oedema
Syed Faraz Kazim,1 Muhammad Shahid2
Department of Surgery,1 Department of Emergency Medicine,2 Aga Khan University Hospital, Karachi, Pakistan.

Abstract
A case of anaphylaxis and angioedema induced by
angiotensin II receptor blocker (ARB), losartan is reported. A
37 years old hypertensive female presented to the Emergency
Department with swelling over the face especially the lips,
urticarial rash all over the body, and dyspnoea within an hour
of losartan administration. She did not have any previous
history of drug allergies. The patient was managed with
epinephrine. Although angioneurotic oedema and anaphylaxis
are well documented adverse effects of angiotensin converting
enzyme (ACE) inhibitors, very few cases of these adverse
reactions with ARBs have been reported in medical literature.

Introduction
Anaphylaxis is an allergic, IgE mediated,
hypersensitivity reaction that is rapid in onset and can be lifethreatening.1 Angioedema is an asymmetric, non-pitting
swelling of loose tissue, usually skin. Laryngeal swelling from
angioedema may lead to severe respiratory distress.2 The most
common etiologic agents of anaphylaxis and angioedema
include drugs, insect bites, foods and food additives, transfusion
of blood and blood products, radio- contrast media, and latex.1,2
In this report, we describe a case of anaphylaxis and
angioedema associated with angiotensin II receptor blocker
(ARB), losartan.

Case Report
A 37 years old female presented to the Emergency
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Department (ED) of Aga Khan University Hospital (AKUH),
Karachi, with complaints of facial swelling especially over the
lips, generalized rash all over the body, and dyspnoea for two
hours. The history of presenting complaints revealed that she
was started that morning on losartan 50mg by a family
physician for the control of hypertension. The patient was
previously taking captopril, which incited cough, and was
therefore stopped. The patient had no previous history of
anaphylaxis or angioedema. Within the first 60 minutes of
starting medication, she developed difficulty in breathing
along with facial swelling and urticarial rash all over the body.
The patient presented to the ED, approximately two and half
hours after intake of the medication. On arrival in the ED, her
blood pressure was 120/85 mmHg, pulse rate 90 /minute,
temperature 37.2°C, respiratory rate 22/minute; and oxygen
saturation of 94% at room air. She experienced cold sweats all
over the body. Her clinical examination was otherwise within
normal limits. Based on her history and physical examination,
a diagnosis of anaphylaxis and angioedema was made. Her
baseline laboratory investigations including complete blood
count (CBC), electrolytes, blood urea nitrogen (BUN) and
creatinine, and liver function tests were done and they were
within normal limits. Her serum IgE levels, however, were
marginally raised. She was managed with epinephrine
followed by ranitidine, clemastine, and hydrocortisone. Her
symptoms resolved within an hour of treatment. The patient
remained in the ED for two more hours and was subsequently
transferred to the Internal Medicine Ward. She was discharged
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after 24 hours of observation.

Discussion
Losartan is an orally effective ARB, used for the
treatment of hypertension, cardiac disease, and renal disease.3,4
The drug was approved by United States Food and Drug
Administration for clinical use in 1995.3,4 The more widely
used angiotensin converting enzyme (ACE) inhibitors, such as
captopril, are well known to cause cough (5 to 20% of patients)
and angioneurotic oedema (0.1 to 0.2% of patients) because of
the accumulation of bradykinin.3 Initially, it was hypothesized
that since losartan does not have ACE activity, it would not
block the degradation of bradykinin; and hence there would not
be an increase in bradykinin levels.3-6 The drug was thus
publicized to be free of above mentioned adverse effects.
Nevertheless, even according to the manufacturers,
angioedema occured in 1 out of 4058 initially treated patients.4
Additionally, few other cases have been reported in medical
literature during the past years.5 Acker and Greenberg in 1995
reported a case of angioedema in a patient induced within 30
minutes of administration of losartan.6 Their case was a 52
years old male, who had a history of focal segmental
glomerulosclerosis and was prescribed losartan for the control
of hypertension. Just as the patient being reported here, he too
had previously received an ACE inhibitor, captopril, which was
discontinued because he was experiencing cough with it. He
too did not have any previous history of angioedema. He
however, did have a history of allergy to radiographic contrast
material. Lately in 2005, Nielson7 reported a case of
hypotensive shock and angioneurotic oedema associated with
ARB, irbesartan. According to few authors treatment with
losartan may cause anaphylaxis during haemodialysis.8,9 The
better documented anaphylactic reactions associated with ACE
inhibitors during dialysis with AN69 membranes have been
shown to be due to activation of bradykinin along with
bradykinin effects on prostaglandins, leukotrienes, and
substance P.10 However, as mentioned earlier, if ARBs do not
have any effect on bradykinin metabolism, they should not
cause these adverse reactions.
More recent studies have shown that ARBs may in fact
increase the bradykinin levels.7,11-13 Campbell et al have
shown that losartan increases the bradykinin levels by twofold
in hypertensive patients.11 ARBs bind to type 1 angiotensin II
receptors (AT1). This binding blocks the cardiovascular
effects induced by angiotensin II, e.g. vasoconstriction, water
and salt retention, aldosterone synthesis and release.
Angiotensin II can still bind to type 2 receptors. This binding
may counteract some or all of the above mentioned effects
mediated via AT1 receptors, and may do so by increasing
bradykinin and nitric oxide.12 Other mechanisms by which
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ARB may increase bradykinin is by inhibiting ACE11 and
neutral endopeptidase (NEP).13 Thus, ARB mediated increase
in bradykinin may be responsible for anaphylaxis and
angioedema seen with losartan. This may be a class effect, and
thus other ARBs should not be prescribed to patients with
documented anaphylaxis and/or angioedema secondary to any
ARB. Nonetheless, anaphylaxis in the patient under review
may be an allergic reaction to antigenic properties of losartan;
and thus other ARBs may be well tolerated.
Losartan and other ARBs are widely used in clinical
practice in Pakistan. To the best of our knowledge, this is the
first case of an ARB associated anaphylaxis and angioedema
from Pakistan.

Conclusion
In conjunction with the previously published reports,
our case of losartan associated angioedema and anaphylaxis
strengthens the evidence that ARBs increase bradykinin
levels; and thus may cause allergic reactions in susceptible
patients. This may be a class effect; and thus other ARBs
should be avoided in such patients. Further research is
warranted to explore this side effect of losartan. Meanwhile,
the drug should be prescribed with caution.
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